Inhibitor Therapeutics INTI
OTC INTI
$0.09 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Invested Capital (2013 - 2026)

Inhibitor Therapeutics' (INTI) quarterly Invested Capital came in at $28981.0 in Q1 2026, up 11.52% YoY from $25987.0 in Q1 2025, and up 17.22% on a QoQ basis from $24724.0 in Q4 2025.

Inhibitor Therapeutics (INTI) Invested Capital (2013 - 2026) Analysis & Trends

Inhibitor Therapeutics (INTI) has 4 years of Invested Capital data on file, last reported at $28981.0 in Q1 2026.

  • Quarterly Invested Capital rose 11.52% year-over-year to $28981.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107147.0 (up 312.31% YoY) and the FY2025 annual result came in at $24724.0, changed N/A from the prior year.
  • Invested Capital advanced to $28981.0 in Q1 2026, from $24724.0 in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $28981.0 in Q1 2026 to a low of $24724.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 37.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 190.90 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 1.45 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - 380.00 Mn
10 Inhibitor Therapeutics 15.64 Mn 15.64 Mn - 26,262.00

Historic Data

Download Data
DateValue
Mar 31, 2026 28,981.00
Dec 31, 2025 24,724.00
Sep 30, 2025 27,455.00
Jun 30, 2025 25,987.00
Mar 31, 2025 25,987.00
Dec 31, 2014 273,638.00
Sep 30, 2014 639,768.00
Jun 30, 2014 639,768.00
Mar 31, 2014 474,874.00
Dec 31, 2013 366,130.00
Sep 30, 2013 196,588.00